Telavancin: A Novel Lipoglycopeptide

• Published in: Clinical infectious diseases Vol. 49; no. 12; pp. 1908 - 1914
• Main Authors: Saravolatz, Louis D., Stein, Gary E., Johnson, Leonard B.
• Format: Journal Article
• Language: English
• Published: Oxford The University of Chicago Press 15.12.2009; University of Chicago Press; Oxford University Press
• Subjects: Aminoglycosides - adverse effects; Aminoglycosides - pharmacokinetics; Aminoglycosides - pharmacology; Aminoglycosides - therapeutic use; Anti-Bacterial Agents - pharmacology; Antibacterial agents; Antibiotics; Antibiotics. Antiinfectious agents. Antiparasitic agents; Antimicrobials; Biological and medical sciences; Cell membranes; Chemistry, Pharmaceutical; Clinical trials; Dosage; Glycopeptides; Humans; Infections; Infectious diseases; Medical sciences; Medical treatment; Methicillin resistant staphylococcus aureus; Peptides; Pharmacokinetics; Pharmacology. Drug treatments; REVIEWS OF ANTI-INFECTIVE AGENTS; Skin; Staphylococcus aureus; Staphylococcus infections; Infection; Telavancin; Antibiotic; Antibacterial agent
• ISSN: 1058-4838; 1537-6591; 1537-6591
• DOI: 10.1086/648438

Telavancin, a derivative of vancomycin, is a lipoglycopeptide antibiotic that has been shown to be effective for the treatment of complicated skin and skin-structure infections. It has also been effective in the treatment of gram-positive pneumonia. This antibiotic has a dual mechanism of action by inhibiting peptidoglycan synthesis and causing membrane depolarization. Telavancin is consistently active against Staphylococcus aureus , including methicillin-resistant S. aureus , vancomycin-intermediate S. aureus , linezolid-resistant S. aureus , and daptomycin-nonsusceptible strains. The drug is usually administrated intravenously at 10 mg/kg every 24 h. Telavancin is excreted by the kidneys, and thus, dosage adjustments are required in cases of renal failure. Clinical trials have demonstrated non-inferiority, compared with vancomycin, in the treatment of complicated skin and skin-structure infections and pneumonia. Telavancin is associated with higher rates of renal events, altered taste, nausea, and vomiting but lesser rates of pruritus and infusion-related events, compared with vancomycin.